The effect of the addition of sodium compounds in the liquid-phase hydrodechlorination of chlorobenzene over palladium catalysts

The hydrodechlorination of chlorobenzene over supported palladium catalysts has been studied. The palladium catalysts: deactivate as the reaction proceeds due to the HCl formed as by-product. The effect of the addition of sodium compounds has been analysed for the neutralisation of HCl. When NaOH was added to the reaction mixture, no beneficial effect was observed due to the detrimental effect of the alkaline medium on the textural and metallic properties of the catalysts. Doping the support with NaOH prior to impregnation with the metal precursor leads (after calcination and reduction) to catalysts with better activity and tolerance to deactivation, especially those obtained when using PdCl2 as the metal precursor. Low metal dispersion and the capture of chloride by forming NaCl are the: main factors contributing to the: improved catalytic properties. Finally, doping the catalysts with NaOH or NaNO3, after reduction of the metal precursor leads to a moderate increase in initial activity and final conversion, although NaOH impregnation also gave rise to support corrosion and metal dispersion modification. (C) 2001 Elsevier Science B.V, All rights reserved.

Src and ADAM-17-Mediated Shedding of Transforming Growth Factor-alpha Is a Mechanism of Acute Resistance to TRAIL

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L) has emerged as a promising anticancer agent. However, resistance to TRAIL is likely to be a major problem, and sensitization of cancer cells to TRAIL may therefore be an important anticancer strategy. In this study, we examined the effect of the epidermal growth factor receptor (EGFR)tyrosine kinase inhibitor (TKI) gefitinib and a human epidermal receptor 2 (HER2)-TKI (M578440) on the sensitivity of human colorectal cancer (CRC) cell lines to recombinant human TRAIL (rhTRAIL). A synergistic interaction between rhTRAIL and gefitinib and rhTRAIL and M578440 was observed in both rhTRAIL-sensitive and resistant CRC cells. This synergy correlated with an increase in EGFR and HER2 activation after rhTRAIL treatment. Furthermore, treatment of CRC cells with rhTRAIL resulted in activation of the Src family kinases (SFK). Importantly, we found that rhTRAIL treatment induced shedding of transforming growth factor-alpha (TGF-alpha) that was dependent on SFK activity and the protease ADAM-17. Moreover, this shedding of TGF-alpha was critical for rhTRAIL-induced activation of EGFR. In support of this, SFK inhibitors and small interfering RNAs targeting ADAM-17 and TGF-alpha also sensitized CRC cells to rhTRAIL-mediated apoptosis. Taken together, our findings indicate that both rhTRAIL-sensitive and resistant CRC cells respond to rhTRAIL treatment by activating an EGFR/HER2-mediated survival response and that these cells can be sensitized to rhTRAIL using EGFR/HER2-targeted therapies. Furthermore, this acute response to rhTRAIL is regulated by SFK-mediated and ADAM-17-mediated shedding of TGF-alpha, such that targeting SFKs or inhibiting ADAM-17, in combination with rhTRAIL, may enhance the response of CRC tumors to rhTRAIL. [Cancer Res 2008;68(20):8312-21]